The theory was that biotechs would become the innovation engine of Big Pharma, creating the products that drug companies would commercialize. Now, the trend has reversed itself. Drug companies are helping biotechs fill their pipelines, but with this twist--biotechs are then going out and selling those products to someone else at higher valuations.
You may also be interested in...
Sandoz is benefiting from its focus on a “pure play” generics and biosimilars model that is unique among its peers, CEO Richard Saynor tells Generics Bulletin in an exclusive interview.
The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution.
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.